Amy Rocklin - Neogen Chief Secretary
| NEOG Stock | USD 10.23 0.07 0.68% |
Executive
Amy Rocklin is Chief Secretary of Neogen
| Age | 53 |
| Address | 620 Lesher Place, Lansing, MI, United States, 48912-1595 |
| Phone | (517) 372-9200 |
| Web | https://www.neogen.com |
Amy Rocklin Latest Insider Activity
Tracking and analyzing the buying and selling activities of Amy Rocklin against Neogen stock is an integral part of due diligence when investing in Neogen. Amy Rocklin insider activity provides valuable insight into whether Neogen is net buyers or sellers over its current business cycle. Note, Neogen insiders must abide by specific rules, including filing SEC forms every time they buy or sell Neogen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Amy Rocklin over six months ago Disposition of 563 shares by Amy Rocklin of Neogen at 11.96 subject to Rule 16b-3 |
Neogen Management Efficiency
The Neogen's current Return On Tangible Assets is estimated to increase to -0.0089. The current Return On Capital Employed is estimated to decrease to 0.01. At this time, Neogen's Other Current Assets are most likely to increase significantly in the upcoming years. The Neogen's current Total Current Assets is estimated to increase to about 711.5 M, while Other Assets are projected to decrease to 1.09. Neogen's management efficiency ratios could be used to measure how well Neogen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Weimin MS | Medpace Holdings | N/A | |
| Toralf Haag | Qiagen NV | 54 | |
| Derek Bomar | RadNet Inc | 57 | |
| Michael Murdock | RadNet Inc | 70 | |
| John Wegener | Exagen Inc | 55 | |
| Stephane Bancel | Qiagen NV | 47 | |
| Nigel Clerkin | ICON PLC | 50 | |
| MD MBA | Aclaris Therapeutics | N/A | |
| Scott Leffler | Myriad Genetics | 49 | |
| JeanPascal Viola | Qiagen NV | N/A | |
| Matthew Scalo | Myriad Genetics | N/A | |
| Jennifer Fox | Myriad Genetics | 52 | |
| Samraat Raha | Myriad Genetics | 52 | |
| Fernando Beils | Qiagen NV | N/A | |
| Alistair Grenfell | IQVIA Holdings | N/A | |
| Gina MPH | Medpace Holdings | N/A | |
| Elizabeth Tallett | Qiagen NV | 71 | |
| Patrick Burke | Myriad Genetics | N/A | |
| Andrea Spannheimer | IQVIA Holdings | N/A | |
| Glenn Farrell | Myriad Genetics | N/A | |
| Gail MD | Aclaris Therapeutics | 61 | |
Management Performance
| Return On Equity | -0.16 | ||||
| Return On Asset | 0.0068 |
Neogen Leadership Team
Elected by the shareholders, the Neogen's board of directors comprises two types of representatives: Neogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neogen. The board's role is to monitor Neogen's management team and ensure that shareholders' interests are well served. Neogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Quinlan, CFO, Principal Accounting Officer, VP and Secretary | ||
| Bill Waelke, Head Relations | ||
| John Moylan, Corporate VP | ||
| Dr MBA, Chief Officer | ||
| Julie Mann, VP Officer | ||
| Amy Rocklin, Chief Secretary | ||
| David Naemura, Chief Officer | ||
| Sarah Demey, Administrative Manager | ||
| Robert Donofrio, Vice President - Food Safety Research and Development | ||
| Douglas Jones, COO VP | ||
| John Adent, CEO President |
Neogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.16 | ||||
| Return On Asset | 0.0068 | ||||
| Profit Margin | (0.52) % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 3.01 B | ||||
| Shares Outstanding | 216.94 M | ||||
| Shares Owned By Insiders | 0.37 % | ||||
| Shares Owned By Institutions | 99.63 % | ||||
| Number Of Shares Shorted | 20.09 M | ||||
| Price To Earning | 13.36 X |
Currently Active Assets on Macroaxis
When determining whether Neogen is a strong investment it is important to analyze Neogen's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neogen's future performance. For an informed investment choice regarding Neogen Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neogen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more detail on how to invest in Neogen Stock please use our How to Invest in Neogen guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neogen. If investors know Neogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.86) | Earnings Share (2.19) | Revenue Per Share | Quarterly Revenue Growth 0.007 | Return On Assets |
The market value of Neogen is measured differently than its book value, which is the value of Neogen that is recorded on the company's balance sheet. Investors also form their own opinion of Neogen's value that differs from its market value or its book value, called intrinsic value, which is Neogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neogen's market value can be influenced by many factors that don't directly affect Neogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.